Dr. Michael Lazar

When HIFU is the Right Treatment Option for Prostate Cancer

Is HIFU Prostate Cancer Treatment for You? Since many men are diagnosed with early-stage prostate cancer, often, they must choose between a risky surgical intervention, no treatment at all, or simply monitoring the disease. Among the many treatment options available HIFU falls somewhere in the middle. HIFU, which stands for high intensity focused ultrasound, offers a less invasive, lower risk method of eliminating the prostate in the body with fewer complications. With HIFU physicians are able to target and treat small amounts of tissue, minimizing damage to nerves around the prostate responsible for preserving potency. HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and [...]

2019-05-14T09:32:18-07:00May 14th, 2019|

New Non-invasive Treatment for Prostate Cancer Adopted by Local Surgeon

*Urologist Robert Pugach, MD treated patients for over 10 years with HIFU before he underwent HIFU himself. Prostate cancer is a very common disease – about 1 in 9 men with be diagnosed in his lifetime. The good news is that it is also very treatable, especially if diagnosed early. Unfortunately, many traditional treatments for prostate cancer have a high risk of unwanted side effects which leave men with lifelong problems like loss of sexual function and urinary incontinence. However, a non-invasive treatment called HIFU is now available for men with localized prostate cancer: HIFU, which stands for High Intensity Focused Ultrasound, is as effective as surgery or radiation in eliminating cancer with lower risk of side effects. HIFU uses ultrasound energy to heat and [...]

2019-05-02T08:06:13-07:00May 2nd, 2019|

HIFU for prostate cancer offers better outcomes for life

Using high energy ultrasound beams to destroy prostate cancer tumors shown to be as effective as surgery or radiotherapy, but with fewer side effects. A study, carried out at six hospitals across the UK, tracked 625 men with prostate cancer who received a type of treatment called high-intensity focused ultrasound (HIFU). The research is the largest ever study of HIFU treatment used to target prostate tumors. The treatment is similar to a 'lumpectomy' for other cancers -- where doctors remove only tumor cells, leaving as much healthy tissue as possible. The findings, from a number of institutions including Imperial College London and University College London, found that after five years the cancer survival rate from HIFU was 100 per cent. Approximately, 1 in 10 [...]

2019-04-16T09:01:00-07:00April 16th, 2019|

United States sees the biggest drop in prostate cancer rate

Prostate cancer incidence and mortality rates are decreasing or stabilizing in most parts of the world, with the United States recording the biggest drop in incidence, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. Despite the trend toward declining or stabilizing rates, prostate cancer remains the second most commonly diagnosed cancer and the sixth leading cause of cancer death among men worldwide, said the study's lead author, MaryBeth Freeman, MPH, senior associate scientist, Surveillance Research, at the American Cancer Society in Atlanta. "Previous studies have indicated significant variation in prostate cancer rates, due to factors including detection practices, availability of treatment, and genetic factors," Freeman said. "By comparing rates from different countries, we can assess differences in detection practices [...]

2019-04-09T08:34:29-07:00April 9th, 2019|

Compounds in coffee may inhibit the growth of prostate cancer

For the first time, scientists have identified compounds found in coffee which may inhibit the growth of prostate cancer. This is a pilot study, carried out on drug-resistant cancer cells in cell culture and in a mouse model; it has not yet been tested in humans. This work is presented at the European Association of Urology congress in Barcelona, after publication in the peer-reviewed journal The Prostate. Coffee is a complex mixture of compounds which has been shown to influence human health in both positive and negative ways. There is increasing evidence that drinking certain types of coffee is associated with a reduction in incidence of some cancers, including prostate cancers. Now Japanese scientists have studied the effects of two compounds found in coffee, [...]

2019-03-19T08:36:47-07:00March 19th, 2019|

Who is the best candidate for HIFU prostate cancer treatment?

Is HIFU Prostate Cancer Treatment for You? High Intensity Focused Ultrasound (HIFU) is a FDA approved non-invasive therapy for treating prostate cancer. Find out if you qualify for HIFU. HIFU may not be appropriate in every situation, but it is most effective for men who have early stage, localized prostate cancer that has not spread or metastasized outside the prostate. HIFU is an FDA approved precise and targeted therapy that reduces the risk of complications caused by surgery and radiation. HIFU uses ultrasound energy, or sound waves, to heat and destroy specifically targeted areas of tissue. During HIFU, the sound waves pass through healthy tissue without causing damage. At the focal point of the sound waves (like a magnifying glass focusing the rays of [...]

2019-03-12T08:42:04-07:00March 12th, 2019|

No obvious benefits for prostate cancer patients using low-dose aspirin

Low-dose aspirin use does not seem to reduce the overall risk for prostate cancer death at the population level. However, results for extended exposure periods suggest that low-dose aspirin might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis. Findings from a nationwide cohort study are published in Annals of Internal Medicine. Recent studies suggest that aspirin use may improve survival in patients with prostate cancer, but study results are inconclusive. Researchers from the Danish Cancer Society Research Center, Aarhus University Hospital, Copenhagen University Hospital, and University of Southern Denmark used nationwide registries in Denmark to assess the association between postdiagnosis use of low-dose aspirin and prostate cancer mortality. Their analysis did not find convincing evidence of an overall protective [...]

2019-03-05T11:54:54-07:00March 5th, 2019|

Prostate Cancer News: PSA screening significantly reduces the risk for death

After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. After differences in implementation and settings were accounted for, two important prostate cancer screening trials provide compatible evidence that screening reduces prostate cancer mortality. These findings suggest that current guidelines recommending against routine PSA-based screening may be revised. However, questions remain about how to implement screening so that the benefits outweigh the potential harms of over-diagnosis and overtreatment. The findings are published in Annals of Internal Medicine. Current guidelines from the United States Preventive Services Task Force (USPSTF) recommend against prostate-specific antigen (PSA) screening for prostate cancer because the evidence for the test showed very low probability that it would [...]

2019-01-16T09:41:10-07:00January 16th, 2019|

Fewer men are being screened, diagnosed, and treated for prostate cancer

A new study reveals declines in prostate cancer screening and diagnoses in the United States in recent years, as well as decreases in the use of definitive treatments in men who have been diagnosed. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. There is considerable debate surrounding the value of prostate cancer screening with prostate-specific antigen (PSA) testing, and the 2012 United States Preventive Services Task Force (USPSTF) recommendation against PSA testing lies at the center of this debate. This recommendation was made in part due to the potential harms -- such as erectile dysfunction and urinary incontinence -- associated with the treatment of clinically insignificant prostate cancer with radical prostatectomy or radiation. To examine the [...]

2019-01-15T11:04:18-07:00January 15th, 2019|

Study finds needle biopsy procedure may miss higher-risk cancer

Genetic alterations in low-risk prostate cancer diagnosed by needle biopsy can identify men that harbor higher-risk cancer in their prostate glands, Mayo Clinic has discovered. The research, which is published in the January edition of Mayo Clinic Proceedings, found for the first time that genetic alterations associated with intermediate- and high-risk prostate cancer also may be present in some cases of low-risk prostate cancers. The study found the needle biopsy procedure may miss higher-risk cancer that increases the risk of disease progression. Researchers say that men diagnosed with low-risk cancer may benefit from additional testing for these chromosomal alterations. "We have discovered new molecular markers that can help guide men in their decisions about the course of their prostate cancer care," says George Vasmatzis, [...]

2019-01-08T11:03:52-07:00January 8th, 2019|